187 related articles for article (PubMed ID: 17438097)
1. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7.
Lambeck AJ; Crijns AP; Leffers N; Sluiter WJ; ten Hoor KA; Braid M; van der Zee AG; Daemen T; Nijman HW; Kast WM
Clin Cancer Res; 2007 Apr; 13(8):2385-91. PubMed ID: 17438097
[TBL] [Abstract][Full Text] [Related]
2. The chemotactic cytokine interleukin-8--a cyst fluid marker for malignant epithelial ovarian cancer?
Ivarsson K; Runesson E; Sundfeldt K; Haeger M; Hedin L; Janson PO; Brännström M
Gynecol Oncol; 1998 Dec; 71(3):420-3. PubMed ID: 9887242
[TBL] [Abstract][Full Text] [Related]
3. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients.
Hefler L; Tempfer C; Heinze G; Mayerhofer K; Breitenecker G; Leodolter S; Reinthaller A; Kainz C
Br J Cancer; 1999 Nov; 81(5):855-9. PubMed ID: 10555758
[TBL] [Abstract][Full Text] [Related]
4. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer.
Lokshin AE; Winans M; Landsittel D; Marrangoni AM; Velikokhatnaya L; Modugno F; Nolen BM; Gorelik E
Gynecol Oncol; 2006 Aug; 102(2):244-51. PubMed ID: 16434085
[TBL] [Abstract][Full Text] [Related]
5. CASA and Ca 125 in diagnosis and follow-up of advanced ovarian cancer.
Oehler MK; Sütterlin M; Caffier H
Anticancer Res; 1999; 19(4A):2513-8. PubMed ID: 10470185
[TBL] [Abstract][Full Text] [Related]
6. Serum evaluation of interleukin 6 in ovarian cancer patients.
Tempfer C; Zeisler H; Sliutz G; Haeusler G; Hanzal E; Kainz C
Gynecol Oncol; 1997 Jul; 66(1):27-30. PubMed ID: 9234916
[TBL] [Abstract][Full Text] [Related]
7. The value of cancer antigen 125 (CA 125) during treatment and follow-up of patients with ovarian cancer.
de Bruijn HW; van der Zee AG; Aalders JG
Curr Opin Obstet Gynecol; 1997 Feb; 9(1):8-13. PubMed ID: 9090475
[TBL] [Abstract][Full Text] [Related]
8. Preoperative serum thrombopoietin levels are higher in patients with ovarian cancer than with benign cysts.
Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
Eur J Obstet Gynecol Reprod Biol; 2008 Sep; 140(1):67-70. PubMed ID: 16359773
[TBL] [Abstract][Full Text] [Related]
9. [-Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma-].
Radke J; Schmidt D; Böhme M; Schmidt U; Weise W; Morenz J
Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):83-7. PubMed ID: 8647364
[TBL] [Abstract][Full Text] [Related]
10. [Ovarian carcinoma antigen (CA 125) and ovarian cancer (clinical follow-up and prognostic studies)].
Göcze P; Vahrson H
Orv Hetil; 1993 Apr; 134(17):915-8. PubMed ID: 8479736
[TBL] [Abstract][Full Text] [Related]
11. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer.
Hefler LA; Zeillinger R; Grimm C; Sood AK; Cheng WF; Gadducci A; Tempfer CB; Reinthaller A
Gynecol Oncol; 2006 Nov; 103(2):512-7. PubMed ID: 16750560
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder.
Tsukishiro S; Suzumori N; Nishikawa H; Arakawa A; Suzumori K
Gynecol Oncol; 2006 Sep; 102(3):542-5. PubMed ID: 16510173
[TBL] [Abstract][Full Text] [Related]
13. Is serum CA 125 at the time of relapse a prognostic indicator for further survival prognosis in patients with ovarian cancer?
Makar AP; Kristensen GB; Børmer OP; Tropé CG
Gynecol Oncol; 1993 Apr; 49(1):3-7. PubMed ID: 8482556
[TBL] [Abstract][Full Text] [Related]
14. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.
Topalak O; Saygili U; Soyturk M; Karaca N; Batur Y; Uslu T; Erten O
Gynecol Oncol; 2002 Apr; 85(1):108-13. PubMed ID: 11925128
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of cancer antigen 125 (CA 125) in ovarian cancer.
Crombach G; Zippel HH; Würz H
Cancer Detect Prev; 1985; 8(1-2):135-9. PubMed ID: 3864535
[TBL] [Abstract][Full Text] [Related]
16. Expression of IL-10 in patients with ovarian carcinoma.
Mustea A; Könsgen D; Braicu EI; Pirvulescu C; Sun P; Sofroni D; Lichtenegger W; Sehouli J
Anticancer Res; 2006; 26(2C):1715-8. PubMed ID: 16617566
[TBL] [Abstract][Full Text] [Related]
17. Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology.
Dehqanzada ZA; Storrer CE; Hueman MT; Foley RJ; Harris KA; Jama YH; Shriver CD; Ponniah S; Peoples GE
Oncol Rep; 2007 Mar; 17(3):687-94. PubMed ID: 17273752
[TBL] [Abstract][Full Text] [Related]
18. [Serum levels of interleukin-10 in patients with ovarian carcinoma in response to chemotherapy].
Zakrzewska I; Poznański J
Przegl Lek; 2003; 60(1):18-20. PubMed ID: 12884640
[TBL] [Abstract][Full Text] [Related]
19. Normal interleukin-10 serum level opposed to high serum levels of carbohydrate antigen 19-9 and cancer antigens 125 and 50 in a case of true splenic cyst.
Lieto E; Castellano P; Ferraraccio F; Orditura M; De Vita F; Romano C; Pignatelli C; Galizia G
Arch Med Res; 2003; 34(2):145-8. PubMed ID: 12700012
[TBL] [Abstract][Full Text] [Related]
20. [The role of tumor marker CA 125 in the treatment of ovarian cancer].
Porsbjerg CM; Sørensen JB; Lund BA
Ugeskr Laeger; 1998 Feb; 160(7):995-1000. PubMed ID: 9477746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
